Athenex CEO Informs Shareholders of Unrelated Matter Regarding Past Board Membership at Porton Pharma

NEXT STORY
EyePoint Pharmaceuticals Signs Exclusive License Agreement with Equinox Science to Develop Tyrosine Kinase Inhibitor Vorolanib for the Treatment of Wet AMD, Diabetic Retinopathy and Retinal Vein Occlusion
PREV STORY
Immunicum AB (publ) meddelar att abstrakten inför ASCO-SITC Clinical Immuno-Oncology Symposium publicerats
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Novartis delivered strong Q2 performance, driven by momentum of key growth brands. FY 2021 guidance unchanged.

author_avatar
NASDAQ Market News

Galera Therapeutics Announces Presentation of Avasopasem Manganese (GC4419) Two-Year Tumor Outcomes Data at 2020 Multidisciplinary Head and Neck Cancers Symposium

author_avatar
NASDAQ Market News

Tarsus Medical Group Officially Announces Rebrand of South Beach Symposium to LiVDerm

author_avatar
NASDAQ Market News